These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

850 related items for PubMed ID: 26512780

  • 1. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X, Wu JB, Chung LW, Huang WC.
    Oncotarget; 2015 Dec 01; 6(38):41018-32. PubMed ID: 26512780
    [Abstract] [Full Text] [Related]

  • 2. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.
    Li X, Chen YT, Hu P, Huang WC.
    Mol Cancer Ther; 2014 Apr 01; 13(4):855-66. PubMed ID: 24493696
    [Abstract] [Full Text] [Related]

  • 3. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
    Karanika S, Karantanos T, Kurosaka S, Wang J, Hirayama T, Yang G, Park S, Golstov AA, Tanimoto R, Li L, Thompson TC.
    Mol Cancer; 2015 Jun 19; 14():122. PubMed ID: 26084402
    [Abstract] [Full Text] [Related]

  • 4. Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
    Xie H, Li C, Dang Q, Chang LS, Li L.
    Oncotarget; 2016 Jan 12; 7(2):1341-53. PubMed ID: 26625310
    [Abstract] [Full Text] [Related]

  • 5. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J, Liu W, Fan YZ, He DL, Li L.
    Theranostics; 2018 Jan 12; 8(1):109-123. PubMed ID: 29290796
    [Abstract] [Full Text] [Related]

  • 6. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H, Klotz LH, Sugar LM, Kiss A, Venkateswaran V.
    Biochem Biophys Res Commun; 2015 Aug 28; 464(3):848-54. PubMed ID: 26182875
    [Abstract] [Full Text] [Related]

  • 7. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K, Suzuki K.
    Biochem Biophys Res Commun; 2012 Mar 16; 419(3):584-9. PubMed ID: 22387542
    [Abstract] [Full Text] [Related]

  • 8. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma.
    Gao S, Shi Z, Li X, Li W, Wang Y, Liu Z, Jiang J.
    Oncol Rep; 2018 Apr 16; 39(4):1919-1929. PubMed ID: 29436682
    [Abstract] [Full Text] [Related]

  • 9. Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
    Gonzalez-Moreno O, Segura V, Serrano D, Nguewa P, de las Rivas J, Calvo A.
    Int J Cancer; 2007 Sep 15; 121(6):1197-204. PubMed ID: 17520673
    [Abstract] [Full Text] [Related]

  • 10. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.
    Eur Urol; 2015 Jun 15; 67(6):1177-1185. PubMed ID: 25220373
    [Abstract] [Full Text] [Related]

  • 11. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
    Howard EW, Lee DT, Chiu YT, Chua CW, Wang X, Wong YC.
    Int J Cancer; 2008 May 01; 122(9):1941-8. PubMed ID: 18183597
    [Abstract] [Full Text] [Related]

  • 12. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME.
    Int J Cancer; 2008 May 15; 122(10):2368-76. PubMed ID: 18240145
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M, Rachagani S, Muniyan S, Seshacharyulu P, Johansson SL, Datta K, Lin MF, Batra SK.
    Oncotarget; 2015 Feb 28; 6(6):3887-903. PubMed ID: 25682877
    [Abstract] [Full Text] [Related]

  • 14. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway.
    Singh SK, Banerjee S, Acosta EP, Lillard JW, Singh R.
    Oncotarget; 2017 Mar 07; 8(10):17216-17228. PubMed ID: 28212547
    [Abstract] [Full Text] [Related]

  • 15. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook DC, Vassilev LT.
    Mol Cancer; 2011 May 03; 10():49. PubMed ID: 21539745
    [Abstract] [Full Text] [Related]

  • 16. Silencing of CDC20 suppresses metastatic castration-resistant prostate cancer growth and enhances chemosensitivity to docetaxel.
    Li K, Mao Y, Lu L, Hu C, Wang D, Si-Tu J, Lu M, Peng S, Qiu J, Gao X.
    Int J Oncol; 2016 Oct 03; 49(4):1679-85. PubMed ID: 27633058
    [Abstract] [Full Text] [Related]

  • 17. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY, Lu L, Adams M, Meyer B, Bartlett JB, Dalgleish AG, Galustian C.
    Prostate; 2012 Jun 01; 72(8):856-67. PubMed ID: 21968939
    [Abstract] [Full Text] [Related]

  • 18. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H, Wang Q, Kawano Y, Arafat T, Böhler T, Winkler M, Cooper C, Pchejetski D.
    Oncotarget; 2016 Dec 06; 7(49):80943-80956. PubMed ID: 27821815
    [Abstract] [Full Text] [Related]

  • 19. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP.
    Cancer Res; 2004 Oct 15; 64(20):7426-31. PubMed ID: 15492266
    [Abstract] [Full Text] [Related]

  • 20. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K, Matsuoka I, Kajiwara S, Sasaki T, Miki M, Kato M, Kanda H, Arima K, Shiraishi T, Sugimura Y.
    J Cancer Res Clin Oncol; 2018 Jan 15; 144(1):89-98. PubMed ID: 29098395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.